Rigor Reviewed

Rigor-Reviewed Manuscript

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.

Name: Αlpha¹ Rigor Record — Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Item: Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Rating: 96
Author: Αlpha¹

Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.25★ (Weak), 0 critical, 3 high issues for “Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsCitations & links (capped) ×10−1★
IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingStudy design partially met−0.25★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced6 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Study-design details incomplete (controls, blinding, power)Assessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 2 open-label single-arm trial is well-conducted and clearly reported, with strong scientific premise, adequate ethics, resource identification, and data availability. The main weaknesses are the lack of randomization/blinding and formal power analysis, which are inherent to the phase 2 design but limit causal inference.

Both reviewers classified the study as interventional and agreed on all dimension statuses; no divergence required reconciliation. Non-applicable criteria (e.g., randomization, blinding, cell lines, housing) were excluded from scoring. The statistics verification component checked only 1 test (a CI) and found it consistent; other statistics were not machine-verified.

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple prior studies (CheckMate 649, KEYNOTE-590, RATIONALE-305) and discusses the limitations of current therapies (median OS ~14 months, 17% survival beyond 3 years). It provides a logical rationale linking TIGIT/PD-1 dual blockade to enhanced antitumor immunity, supported by preclinical and early-phase clinical data. The paper also addresses limitations of prior research, such as the need for strategies to extend benefit beyond current standards.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior work on PD-1 inhibitors, TIGIT biology, and preclinical/clinical evidence supporting the combination.

Evidence

paraphrase[Introduction, paragraph 1]

“The addition of programmed cell death protein 1 (PD-1) inhibitors to chemotherapy has reshaped first-line treatment for metastatic gastroesophageal cancer, expanding therapeutic options and improving outcomes.”

paraphrase[Introduction, paragraph 2]

“TIGIT suppresses T cell activation by outcompeting the activating receptor CD226 for the shared ligand CD155.”

paraphrase[Introduction, paragraph 1]

“However, durable benefit remains limited, with a median overall survival (OS) of approximately 14 months and only about 17% of patients living beyond 3 years.”

PASSReviewer 2· 90% conf

The paper establishes a strong scientific premise by citing prior work on PD-1 inhibitors, TIGIT biology, and preclinical/clinical evidence for the combination, and clearly links this to the study rationale.

Evidence

paraphrase[Introduction, paragraph 1]

paraphrase[Introduction, paragraph 2]

“TIGIT expression correlates with PD-1, particularly in tumor-infiltrating T cells, and the two pathways have distinct, nonredundant roles in regulating antitumor immunity.”

paraphrase[Introduction, paragraph 1]

“However, durable benefit remains limited, with a median overall survival (OS) of approximately 14 months and only about 17% of patients living beyond 3 years.”

The study is open-label (no blinding) and single-arm (no randomization), which is appropriate for a phase 2 proof-of-concept but limits rigor. The sample size justification is descriptive, not powered for hypothesis testing. Inclusion/exclusion criteria are described, and the analysis population (treated) is defined. Outlier handling is not explicitly addressed, but the analysis population is pre-specified. Controls are not applicable as there is no comparator arm. Independent replication is not applicable as this is a single trial.

Sub-criteria

controlsN/A

power analysisINADEQUATE

blinding levelsINADEQUATE

outlier handlingNOT REPORTED

randomization unitN/A

inclusion exclusionADEQUATE

randomization methodN/A

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 85% conf

The study design is a single-arm, open-label phase 2 trial with no randomization or blinding, and the sample size is based on an estimation framework rather than formal power analysis.

Evidence

direct quote[Methods, Study design]

“The study is open label, so investigators were not blinded to the allocation of enrolled patients.”